vs

Side-by-side financial comparison of Ellington Financial Inc. (EFC) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $78.2M, roughly 1.9× Ellington Financial Inc.). Ellington Financial Inc. runs the higher net margin — 28.9% vs -5.5%, a 34.4% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 8.7%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 1.8%).

Ellington Management Group is an American hedge fund firm. As of June 2019, the firm was reportedly managing $8.5 billion in structured products and other credit instruments.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

EFC vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.9× larger
TARS
$151.7M
$78.2M
EFC
Growing faster (revenue YoY)
TARS
TARS
+119.7% gap
TARS
128.4%
8.7%
EFC
Higher net margin
EFC
EFC
34.4% more per $
EFC
28.9%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
1.8%
EFC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EFC
EFC
TARS
TARS
Revenue
$78.2M
$151.7M
Net Profit
$22.6M
$-8.4M
Gross Margin
Operating Margin
7.4%
-5.3%
Net Margin
28.9%
-5.5%
Revenue YoY
8.7%
128.4%
Net Profit YoY
-26.2%
63.8%
EPS (diluted)
$0.10
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EFC
EFC
TARS
TARS
Q4 25
$78.2M
$151.7M
Q3 25
$82.8M
$118.7M
Q2 25
$92.5M
$102.7M
Q1 25
$82.9M
$78.3M
Q4 24
$72.0M
$66.4M
Q3 24
$67.0M
$48.1M
Q2 24
$91.2M
$40.8M
Q1 24
$75.5M
$27.6M
Net Profit
EFC
EFC
TARS
TARS
Q4 25
$22.6M
$-8.4M
Q3 25
$29.5M
$-12.6M
Q2 25
$42.9M
$-20.3M
Q1 25
$31.6M
$-25.1M
Q4 24
$30.7M
$-23.1M
Q3 24
$16.2M
$-23.4M
Q2 24
$52.3M
$-33.3M
Q1 24
$26.9M
$-35.7M
Operating Margin
EFC
EFC
TARS
TARS
Q4 25
7.4%
-5.3%
Q3 25
31.1%
-12.2%
Q2 25
38.3%
-21.6%
Q1 25
37.3%
-33.5%
Q4 24
28.0%
-36.8%
Q3 24
24.0%
-52.3%
Q2 24
52.8%
-81.6%
Q1 24
42.2%
-136.5%
Net Margin
EFC
EFC
TARS
TARS
Q4 25
28.9%
-5.5%
Q3 25
35.7%
-10.6%
Q2 25
46.4%
-19.8%
Q1 25
38.2%
-32.1%
Q4 24
42.6%
-34.8%
Q3 24
24.1%
-48.7%
Q2 24
57.4%
-81.6%
Q1 24
35.6%
-129.4%
EPS (diluted)
EFC
EFC
TARS
TARS
Q4 25
$0.10
$-0.17
Q3 25
$0.29
$-0.30
Q2 25
$0.45
$-0.48
Q1 25
$0.35
$-0.64
Q4 24
$0.23
$-0.57
Q3 24
$0.19
$-0.61
Q2 24
$0.62
$-0.88
Q1 24
$0.32
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EFC
EFC
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$201.9M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$1.8B
$343.4M
Total Assets
$19.4B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EFC
EFC
TARS
TARS
Q4 25
$201.9M
$417.3M
Q3 25
$184.8M
$401.8M
Q2 25
$211.0M
$381.1M
Q1 25
$203.3M
$407.9M
Q4 24
$192.4M
$291.4M
Q3 24
$217.7M
$317.0M
Q2 24
$198.5M
$323.6M
Q1 24
$187.5M
$298.5M
Total Debt
EFC
EFC
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
EFC
EFC
TARS
TARS
Q4 25
$1.8B
$343.4M
Q3 25
$1.8B
$335.1M
Q2 25
$1.7B
$332.6M
Q1 25
$1.6B
$342.5M
Q4 24
$1.6B
$224.5M
Q3 24
$1.6B
$237.5M
Q2 24
$1.6B
$252.2M
Q1 24
$1.5B
$275.2M
Total Assets
EFC
EFC
TARS
TARS
Q4 25
$19.4B
$562.2M
Q3 25
$17.8B
$534.6M
Q2 25
$17.1B
$495.0M
Q1 25
$16.6B
$500.8M
Q4 24
$16.3B
$377.0M
Q3 24
$16.0B
$376.3M
Q2 24
$15.1B
$376.8M
Q1 24
$15.1B
$349.3M
Debt / Equity
EFC
EFC
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EFC
EFC
TARS
TARS
Operating Cash FlowLast quarter
$-925.5M
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
0.0%
4.2%
Cash ConversionOCF / Net Profit
-40.92×
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EFC
EFC
TARS
TARS
Q4 25
$-925.5M
$19.3M
Q3 25
$-290.4M
$18.3M
Q2 25
$-210.5M
$-29.4M
Q1 25
$-126.4M
$-20.7M
Q4 24
$-430.5M
$-22.2M
Q3 24
$-141.7M
$-8.7M
Q2 24
$-88.6M
$-14.4M
Q1 24
$-59.5M
$-37.8M
Free Cash Flow
EFC
EFC
TARS
TARS
Q4 25
$13.0M
Q3 25
$16.3M
Q2 25
$-30.4M
Q1 25
$-21.2M
Q4 24
$-22.3M
Q3 24
$-8.9M
Q2 24
$-15.4M
Q1 24
$-38.0M
FCF Margin
EFC
EFC
TARS
TARS
Q4 25
8.6%
Q3 25
13.8%
Q2 25
-29.6%
Q1 25
-27.1%
Q4 24
-33.5%
Q3 24
-18.6%
Q2 24
-37.8%
Q1 24
-137.5%
Capex Intensity
EFC
EFC
TARS
TARS
Q4 25
0.0%
4.2%
Q3 25
1.6%
Q2 25
1.0%
Q1 25
0.8%
Q4 24
0.0%
0.1%
Q3 24
0.0%
0.6%
Q2 24
0.0%
2.5%
Q1 24
0.0%
0.6%
Cash Conversion
EFC
EFC
TARS
TARS
Q4 25
-40.92×
Q3 25
-9.84×
Q2 25
-4.90×
Q1 25
-3.99×
Q4 24
-14.04×
Q3 24
-8.76×
Q2 24
-1.69×
Q1 24
-2.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons